Neoadjuvant chemotherapy in oesophageal adenocarcinoma

Affiliations

¹ Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisa, Pisa 56126, Italy. Electronic address: lorenzo.fornaro@gmail.com.
² Department of Oncology, Ospedale San Bortolo, Azienda ULSS8 Berica - Distretto Est, Vicenza, Italy.

Comment

Lorenzo Fornaro et al. Lancet Oncol. 2017 Nov.

. 2017 Nov;18(11):e640.

doi: 10.1016/S1470-2045(17)30813-6. Epub 2017 Oct 31.

¹ Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisa, Pisa 56126, Italy. Electronic address: lorenzo.fornaro@gmail.com.
² Department of Oncology, Ospedale San Bortolo, Azienda ULSS8 Berica - Distretto Est, Vicenza, Italy.

No abstract available

Comment in

Neoadjuvant chemotherapy in oesophageal adenocarcinoma - Authors' reply.
Alderson D, Nankivell M, Langley R, Cunningham D. Alderson D, et al. Lancet Oncol. 2017 Nov;18(11):e641. doi: 10.1016/S1470-2045(17)30776-3. Epub 2017 Oct 31. Lancet Oncol. 2017. PMID: 29208395 No abstract available.

Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.
Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, Grabsch HI, Langer R, Pritchard S, Okines A, Krysztopik R, Coxon F, Thompson J, Falk S, Robb C, Stenning S, Langley RE. Alderson D, et al. Lancet Oncol. 2017 Sep;18(9):1249-1260. doi: 10.1016/S1470-2045(17)30447-3. Epub 2017 Aug 4. Lancet Oncol. 2017. PMID: 28784312 Free PMC article. Clinical Trial.